# Cardiology (heart failure) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN
- Date: 2026-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Noelani Abernathy-Chen, MD
- Calendar frame: modern shifted

- Requested by: Kawika Lindgren-Morrison, MD

## Reason for consultation

Six weeks of breathlessness, ankle swelling and tiredness in a 66-year-old Native Hawaiian man five years after a heart attack, with NT-proBNP 2,450 pg/mL, old anterior Q waves and an enlarged heart on chest X-ray. Please confirm the diagnosis and cause, advise on guideline-directed medical therapy and its order, the ischemic evaluation and device decisions, and how he can return to swimming and surfing safely. **S**

## History

Mr. Kahanamoku, a 66-year-old Native Hawaiian man who is sheriff of Honolulu and a lifelong swimmer and surfer, is seen at the request of Dr. Lindgren-Morrison on the day of his echocardiogram. At his wish, two members of his ʻohana joined the discussion; he made the decisions. He had a heart attack five years ago, treated with medicines. For about eight weeks he has been breathless on slopes and while paddling, with orthopnea and ankle swelling that have eased on two weeks of furosemide. He has no chest pain, palpitations or fainting. He has never smoked or drunk alcohol. **S**

## Examination

| System | Finding |
|---|---|
| General | Comfortable at rest; blood pressure 134/82, pulse 86; weight 95.0 kg |
| Neck | Jugular venous pressure 3 cm above the sternal angle |
| Cardiovascular | Regular rhythm; displaced apex; soft S3; apical systolic murmur of functional mitral regurgitation |
| Respiratory | Fine crackles at both bases only |
| Extremities | Trace ankle edema |

BP 134/82 mmHg; pulse 86 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 95 kg; BMI 27.8 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Lindgren-Morrison's intake note. ECG: sinus rhythm, Q waves in V1 to V4, QRS 104 ms, no left bundle branch block. Chest X-ray: enlarged heart, upper-lobe venous diversion and small effusions. NT-proBNP 2,450 pg/mL. Echocardiogram this morning: ejection fraction 30% by biplane method, thinned and akinetic anterior wall and apex, left ventricular end-diastolic diameter 62 mm, no thrombus, moderate functional mitral regurgitation, normal right ventricle, estimated pulmonary artery systolic pressure 42 mmHg. Metabolic panel today: potassium 3.9 mmol/L, creatinine 1.08 mg/dL (eGFR 76), magnesium 1.9 mg/dL. Ferritin 62 ng/mL, transferrin saturation 16%, hemoglobin 13.4 g/dL; TSH 2.1; LDL 92 mg/dL on atorvastatin 40 mg. Sodium: 137 mmol/L; Potassium: 3.9 mmol/L; Creatinine: 1.08 mg/dL; eGFR (CKD-EPI 2021): 76 mL/min/1.73 m²; Glucose: 98 mg/dL; Magnesium: 1.9 mg/dL; LVEF by echocardiogram: 30% (low). All results are synthetic.

## Assessment

1. **Diagnosis and cause** (I50.22). Heart failure with reduced ejection fraction, stage C, NYHA class III, from ischemic cardiomyopathy: an ejection fraction of 30% with a thinned, akinetic anterior wall and apex in the territory of the old anterior infarction, and Q waves to match. The mitral regurgitation is functional, from the dilated ventricle. TSH and blood count exclude thyroid disease and anemia as contributors; he does not drink alcohol. **S**
2. **Ischemic evaluation** (I25.2). Invasive coronary angiography is reasonable in new HFrEF with a likely coronary cause, to define the anatomy and look for disease that revascularization could help, especially in vessels other than the infarct artery. A thinned, akinetic wall of 5 mm or less is unlikely to recover even if its artery is opened. **S**
3. **Guideline-directed medical therapy** (I50.22). Start all four classes within weeks rather than months. Stop lisinopril and begin sacubitril-valsartan 24/26 mg twice daily at least 36 hours after the last lisinopril dose, to avoid angioedema. Replace metoprolol tartrate, which is not one of the beta-blockers proven in heart failure, with carvedilol 3.125 mg twice daily. Start empagliflozin 10 mg now. Add spironolactone 12.5 mg at the next visit if potassium is below 5.0 mmol/L and eGFR above 30. Then raise one medicine every two weeks toward target doses (sacubitril-valsartan 97/103 mg and carvedilol 25 mg twice daily) as blood pressure, heart rate, potassium and kidney function allow, with a metabolic panel one to two weeks after each change. Keep furosemide at the lowest dose that keeps him dry. Teach sick-day rules. **S**
4. **Iron deficiency** (E61.1). Ferritin below 100 ng/mL is iron deficiency in heart failure even without anemia. Intravenous iron improves symptoms, exercise capacity and quality of life; oral iron does not. Give ferric carboxymaltose 750 mg today and again in two weeks, and check iron studies at about six months. **S**
5. **Defibrillator and resynchronization**. Not now. Repeat the echocardiogram after at least 90 days of optimized therapy; a primary-prevention ICD is indicated if the ejection fraction is still 35% or below with NYHA class II to III and a good expected survival. His QRS of 104 ms does not meet criteria for resynchronization. **S**
6. **Exercise and the ocean**. Exercise training is safe and helps in stable HFrEF. Cardiac rehabilitation for heart failure is covered once he has had six weeks of stable therapy and no procedure in the previous six weeks. Until then, walking. After rehabilitation, swimming is reasonable in calm water with a companion; breath-hold diving and big surf should wait until he is clearly stable, because a sudden loss of consciousness in the water is the main danger. Drink water through the morning on the diuretic and empagliflozin. **S**

## Recommendations

1. Stop lisinopril; start sacubitril-valsartan 24/26 mg twice daily 36 hours after the last dose.
2. Change metoprolol tartrate to carvedilol 3.125 mg twice daily.
3. Start empagliflozin 10 mg daily with sick-day rules.
4. Add spironolactone 12.5 mg daily at the next visit if potassium is below 5.0 mmol/L and eGFR above 30.
5. Raise one medicine every two weeks toward target doses, with a metabolic panel one to two weeks after each change.
6. Continue furosemide at the lowest dose that keeps him euvolemic.
7. Ferric carboxymaltose 750 mg intravenously today and in two weeks; iron studies at about six months.
8. Invasive coronary angiography within two weeks.
9. Repeat echocardiogram after at least 90 days of optimized therapy to decide on a primary-prevention ICD.
10. Cardiac rehabilitation for heart failure when eligible, then a graded return to the ocean.
11. Pneumococcal vaccine now; influenza, COVID-19 and RSV vaccines in the autumn.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Lindgren-Morrison, who saw him the same day. The diagnosis, each medicine and the angiography were explained plainly to Mr. Kahanamoku and, at his wish, to members of his ʻohana; he agreed to the plan. **S**

## Follow-up

Dr. Lindgren-Morrison continues his care, with the heart failure nurse for titration. Cardiology will review the angiogram and the repeat echocardiogram, and will see him sooner for worsening symptoms, fainting or palpitations. **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024), American College of Cardiology (J Am Coll Cardiol 2024;83(15):1444-1488)
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017), American Heart Association, American College of Cardiology, and Heart Rhythm Society (Circulation 2018;138(13):e272-e391)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026), Aether Forge
